摘要
目的针对AECOPD(急性加重期慢性阻塞性肺疾病)合并肺栓塞患者,应用利伐沙班实施治疗,观察、分析其临床有效性。方法研究期:2019年1月至2021年6月,纳入98例观察对象展开研究,观察对象为AECOPD合并肺栓塞患者,采用计算机双色球分组法,对患者进行随机分组,并实施不同用药治疗方案:利伐沙班治疗(观察组,n=49),法华林治疗(对照组,n=49),设定临床疗效,肺功能指标,用药不良反应为对照标准,针对不同用药方案的临床疗效差异,展开综合分析。结果临床治疗总有效率对比,观察组患者97.95%高于对照组患者85.71%(P<0.05);治疗后,患者肺功能指标(FVC、FEV1、FEV1/FVC)指标值对比,观察组患者高于对照组患者(P<0.05);治疗期间不良反应(皮肤出血、牙龈出血、黑便)总发生率比较,观察组患者6.12%低于对照组患者24.48%(P<0.05)。结论围绕AECOPD合并肺栓塞患者的治疗,针对性地予以利伐沙班用药,在提升临床疗效,改善肺功能指标上效果显著,同时用药安全系数高,作用明显,值得应用。
Objective To observe and analyze the clinical efficacy of rivaroxaban in patients with AECOPD(acute exacerbation chronic obstructive pulmonary disease)complicated with pulmonary embolism.Methods Study period:from January 2019 to June 2021,98 patients were included in the study.The subjects were patients with AECOPD complicated with pulmonary embolism.The patients were randomly divided into groups by computer two-color ball grouping method,and different drug treatment schemes were implemented:rivaroxaban treatment(observation group,n=49),faharin treatment(control group,n=49),The clinical efficacy,pulmonary function indexes and adverse drug reactions were set as the control standards,and the clinical efficacy differences of different drug regimens were comprehensively analyzed.Results The total effective rate of clinical treatment in the observation group was 97.95%higher than 85.71%in the control group(P<0.05);After treatment,the indexes of pulmonary function(FVC,FEV1,FEV1/FVC)in the observation group were higher than those in the control group(P<0.05);The total incidence of adverse reactions(skin bleeding,gingival bleeding and black stool)in the observation group was 6.12%lower than 24.48%in the control group(P<0.05).Conclusion Focusing on the treatment of patients with AECOPD complicated with pulmonary embolism,rivaroxaban has a significant effect in improving clinical efficacy and pulmonary function indexes.At the same time,it has a high safety factor and obvious effect,which is worthy of application.
作者
董仁达
Dong Renda(Zhuanghe Central Hospital,Zhuanghe 116400,China)
出处
《中国医药指南》
2021年第32期91-93,共3页
Guide of China Medicine
关键词
慢性阻塞性肺疾病急性加重期
肺栓塞
利伐沙班
有效性
Acute exacerbation of chronic obstructive pulmonary disease
Pulmonary embolism
Rivaroxaban
Effectiveness
